Autopsy report · NCT03250117
Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
Cause of deathFunding or business
“This study was terminated for reasons not related to efficacy or safety”
Life of this trial
- Registered 2 months before it started.
- Ran for about 7 months before it stopped.
- 6 participants enrolled.
- Results were posted on the registry 4 years 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Titan Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Parkinson Disease
- Interventions
- Ropinirole oral product; Ropinirole Implant
- Participants
- 6
- Sites
- 3
- Countries
- United States
Trials that died the same way
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
“This study was terminated due to limited efficacy and not due to safety reasons” - A Study of Tadalafil for Duchenne Muscular Dystrophy
“The study is being terminated for lack of efficacy” - Dasatinib in Polycythemia Vera
“This study was terminated due to lack of efficacy.” - An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity
“The study was terminated early due to sponsor decision unrelated to safety or efficacy findings” - A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
“The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.